Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D True

Showing results (241-250 of 315) with videos related to

Pageof 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2019
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate CancerAlexandra N Corella, Ma Victoria Andrea Cabiliza Ordonio, Ilsa Coleman, et al.
The Prostate|March 19, 2016
Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancerMartine P Roudier, Brian R Winters, Ilsa Coleman, et al.
Cancer Discovery|August 15, 2014
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasisJared M Lucas, Cynthia Heinlein, Tom Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2015
SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate CancerXiaotun Zhang, Ilsa M Coleman, Lisha G Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate CancerDiana C DeLucia, Thomas M Cardillo, Lisa Ang, et al.
Oncotarget|February 22, 2018
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancerDebashis Sahoo, Wei Wei, Heidi Auman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptorsEddy J Chen, Adam G Sowalsky, Shuai Gao, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 26, 2026
AI-Informed Architectural Insights of Three-Dimensional Glandular Networks Identify Prostate Cancer Patients at a Higher Risk of Biochemical RecurrenceJennifer Salguero-Lopez, Sebastian Medina, Robert Serafin, et al.
European Urology Focus|September 13, 2016
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate CancerTamara L Lotan, Wei Wei, Carlos L Morais, et al.
Nature Protocols|January 24, 2024
An end-to-end workflow for nondestructive 3D pathologyKevin W Bishop, Lindsey A Erion Barner, Qinghua Han, et al.
Pageof 32

Showing results (241-250 of 315) with videos related to

Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2019
Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate CancerAlexandra N Corella, Ma Victoria Andrea Cabiliza Ordonio, Ilsa Coleman, et al.
The Prostate|March 19, 2016
Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancerMartine P Roudier, Brian R Winters, Ilsa Coleman, et al.
Cancer Discovery|August 15, 2014
The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasisJared M Lucas, Cynthia Heinlein, Tom Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2015
SRRM4 Expression and the Loss of REST Activity May Promote the Emergence of the Neuroendocrine Phenotype in Castration-Resistant Prostate CancerXiaotun Zhang, Ilsa M Coleman, Lisha G Brown, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2020
Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate CancerDiana C DeLucia, Thomas M Cardillo, Lisa Ang, et al.
Oncotarget|February 22, 2018
Boolean analysis identifies CD38 as a biomarker of aggressive localized prostate cancerDebashis Sahoo, Wei Wei, Heidi Auman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2014
Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptorsEddy J Chen, Adam G Sowalsky, Shuai Gao, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 26, 2026
AI-Informed Architectural Insights of Three-Dimensional Glandular Networks Identify Prostate Cancer Patients at a Higher Risk of Biochemical RecurrenceJennifer Salguero-Lopez, Sebastian Medina, Robert Serafin, et al.
European Urology Focus|September 13, 2016
PTEN Loss as Determined by Clinical-grade Immunohistochemistry Assay Is Associated with Worse Recurrence-free Survival in Prostate CancerTamara L Lotan, Wei Wei, Carlos L Morais, et al.
Nature Protocols|January 24, 2024
An end-to-end workflow for nondestructive 3D pathologyKevin W Bishop, Lindsey A Erion Barner, Qinghua Han, et al.
Pageof 32